Amylyx Pharmaceuticals Inc AMLX
$38.66 $1.00 (2.52%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
AMLX Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Amylyx Pharmaceuticals Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Amylyx Pharmaceuticals Inc. Stock Analysis AMLX
United States Health Care Mid Cap Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 136 full-time employees. The company went IPO on 2022-01-07. The firm is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.
Amylyx Pharmaceuticals Inc (AMLX) Chart
Financial Metrics & Statements of Amylyx Pharmaceuticals Inc (AMLX)
FAQ's for Amylyx Pharmaceuticals Inc (AMLX)
- As of August 2026, Amylyx Pharmaceuticals Inc AMLX is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Amylyx Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Amylyx Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Amylyx Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Amylyx Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Amylyx Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Amylyx Pharmaceuticals Inc (AMLX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
